Zarqa’s cancer gene panel is a highly specific and sensitive genetic test designed to detect mutations in genes associated with an increased risk of developing various cancers. The panel includes all known highly penetrant cancer genes, selected based on their potential to significantly impact the development of specific cancers.
Zarqa’s cancer gene panel includes 66 genes known to be linked with a high risk of cancer.
The panel targets genes associated with breast, ovarian, colorectal, gastric, bowel, endometrial, pancreatic, melanoma, renal, and prostate cancers.
Ensures accurate detection of genetic mutations.
ABRAXAS1, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, DICER1, DIS3L2, EPCAM, FANCC, FH, FLCN, GALNT12, HNF1B, HOXB13, KIT, MC1R, MEN1, MET, MITF, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS1, PMS2, POLD1, POLE, POT1, PRSS1, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RECQL, RET, RNF43, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TGFBR2, TP53, TSC1, TSC2, VHL, WT1, XRCC2, XRCC3
Early Detection: Helps in the early identification of genetic predispositions to cancer.
Personalized Medicine: Enables personalized treatment plans based on genetic makeup.
Comprehensive Screening: Covers a broad range of cancers, providing extensive genetic insights.
Discover our advanced genomic testing services tailored for your specific needs. Contact us today to enhance your research with unparalleled accuracy and expertise.
Get The Latest Updates via email. Any time you may unsubscribe
Copyright © 2024 Zarqa Genomics Lab, All rights reserved